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Globally some 250 - 400 million people are chroni cally 
infected with hepatitis B, with sub-Saharan Africa 
(sSA) and South-East Asia being disproportionately 
affected. Compared with the 1.5 million deaths 
annually due to HIV/AIDS, which are declining, 
hepatitis B mortality is on the rise with 500 000 - 1.2 million deaths 
annually. This relates in part to hepatocellular carcinoma (HCC), 
the fifth most common malignancy and the third leading cause of 
cancer-related death worldwide, despite the fact that hepatitis B is an 
entirely vaccine-preventable disease.[1]
Burden of disease
The prevalence of hepatitis B varies geographically, with 45% of 
the global population living in endemic areas (≥8% prevalence 
of hepatitis B surface antigen (HBsAg)), notably the Asia-Pacific 
and sSA region.[1,2] An estimated 65 million people in Africa are 
chronically infected, 2.5 million of them in South Africa (SA).[3,4] In 
endemic countries, the majority of infections occur either perinatally 
or horizontally during early childhood and mostly before the age of 
5 years, although in hepatitis B e-antigen (HBeAg)-positive mothers, 
perinatal transmission is considerably higher. The risk of chronicity 
depends on the age of acquisition, decreasing from 70 - 90% with 
perinatal infection to 25 - 60% in early childhood, 6 - 10% for ages 
5 - 20 years and 1 - 5% for adults aged >20 years.[1] In SA, horizontal 
child-to-child transmission dominates from 6 months to 5 years of age 
and seroprevalence varies between genders, between ethnic groups 
and between urban and rural areas.[4-7] Highlighting this, an Eastern 
Cape Province community-based cross-sectional HBsAg prevalence 
study of 2 299 children aged 0 - 6 years before the introduction of 
hepatitis B immunisation demonstrated that 10.4% children were 
HBsAg-positive, increasing from 8.1% at 0 - 6 months to 15.7% at 
61 - 72 months.[8] Adult-acquired hepatitis B is poorly understood 
in SA, but probably represents a relatively small component of the 
chronic hepatitis B virus (HBV)-infected population.
Given that 15 - 25% of infected patients may develop cirrhosis, 
liver failure or hepatocellular carcinoma, there is a need for improved 
surveillance of acute and chronic HBV infection in Africa to 
better understand the economic burden of HBV infection and its 
complications. In SA there is the dual burden of hepatitis B and HIV, 
although with current antiretroviral regimens containing effective 
anti-HBV drugs, those with co-infection are at least accessing 
therapy. The HIV programme does not automatically test for HBsAg, 
which is unfortunate given that surveillance data would provide 
epidemiological information and allow for targeted interventions 
such as vaccinating partners of those infected with hepatitis B. 
Equally, no antenatal testing is performed, therefore not allowing for 
measures to reduce the risk of mother-to-child transmission of HBV.
Hepatocellular carcinoma
HCC is a significant cause of cancer mortality in sSA, and 46 000 
new cases are diagnosed annually. The age-standardised incidence of 
HCC is as high as 41.2/100 000 persons/year, with prognosis being 
poor and 92% dying within 1 year of the onset of symptoms.[8] HBV, 
a vaccine-preventable disease, accounts for 60 - 80% of HCC, which 
can develop even in the absence of cirrhosis. Furthermore, given that 
the HBV DNA incorporates itself into the host hepatocyte genome, 
even those with occult hepatitis B virus infection (i.e. HBsAg-
negative with detectable serum HBV DNA), or those with previous 
exposure, are at risk of HCC.[9]
Vaccination
The seroprevalence of HBsAg in SA before the introduction of 
hepatitis B vaccination in 1995 ranged from 0.2% to 9.6%, with 
serological evidence of past exposure to hepatitis B (HBsAg-negative, 
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HB core IgG-positive) ranging from 5% to 76%.[3,5,6] Marked 
differences between ethnic groups were noted. HBsAg rates were 
considerably higher in rural areas: 15.5% in the Eastern Cape (former 
rural Transkei), compared with 7.4% in urban Durban and 1.3% in 
Soweto. In rural areas, HBeAg seroprevalence was also higher in 
HBsAg-positive mothers: 12% in HBsAg-positive mothers from 
rural areas compared with 0% in HBsAg-positive pregnant women 
in Soweto. A 2.6:1 male/female predominance is well documented.[5,7]
Universal infant vaccination is the most effective way to reduce the 
global burden of HBV, and the World Health Organization (WHO) 
recommended its incorporation into the Expanded Programme of 
Immunization (EPI) in 1991.[10,11] This proved exemplary in Taiwan, 
where universal vaccination, introduced in 1984, together with a 
catch-up vaccination programme and improved maternal screening, 
resulted in a decrease in the prevalence of HBsAg positivity in children 
aged <15 years from 9.8% in 1984 to 0.7% in 1999.[12,13] Furthermore, 
the prevalence of HCC in children aged 6 - 9 years decreased from 5.2 
cases/million population in 1984 to 1.3/million in the first vaccination 
cohort.[14,15] To date, 183 countries worldwide and 45 in the WHO 
Africa region have incorporated hepatitis B vaccination into the EPI. 
It is estimated that this has prevented more than 1.3 million deaths. 
The global vaccination coverage with three doses is 75% (41 - 89%), 
while birth-dose coverage occurs in 94 WHO member countries. Of 
concern is low birth-dose coverage in countries where there is a high 
risk of perinatal and early childhood transmission. At present, 38 out 
of 56 Global Alliance for Vaccines and Immunization (GAVI)-eligible 
countries are not providing a birth dose, and in Africa birth coverage 
stands at only 23%, with full coverage with three doses, not including a 
birth dose, at only 67% (50 - 79%). In South-East Asia, the rate of birth 
coverage is 10% and that of full coverage 41%.[1,16] The 2010 official 
vaccine coverage rate of 97% in SA is probably overestimated given 
the potentially reduced coverage in rural areas and a WHO reported 
coverage of 56% in 2007.[17]
Birth-dose coverage is important in preventing perinatal trans-
mission. This has been demonstrated in China, where a partnership 
between GAVI and the Chinese government supported a free birth-
dose vaccine; in combination with the up-scaling of the full vaccine 
schedule, <1% of Chinese children are now hepatitis B-infected.[18] 
SA was one of the first 10 countries in Africa to introduce uni versal 
HBV vaccination (6-, 10- and 14-week schedule) in April 1995, but 
currently has no birth dose and no catch-up programme. Obvious 
benefit has already been achieved, with the overall seroprevalence 
of HBsAg declining from 12.8% to 3% in some studies. A 2 - 3-year 
follow-up of 186 infants vaccinated in 1995 with Hepaccine B showed 
seroprotection (anti-hepatitis B surface antibody (anti-HBsAb) 
≥10 mIU/ml) in 93% and 76.8% initially and 3 years later, respectively. 
No children were positive for HBsAg, HBV DNA or anti-hepatitis 
B core antibody (anti-HbcoreAb).[19] In the Eastern Cape, of 1 213 
fully vaccinated 12 - 24-month-old infants born after 1995, none 
were HBsAg-positive, 0.9% (9/986) were anti-HBcoreAb-positive, 
0.3% (4/1 213) were HBV DNA-positive and 84.6% (834/986) had 
protective anti-HBsAb levels. In contrast, 7.8% (39/498) unvaccinated 
12 - 24-month-old infants born before 1995 were HBsAg-positive, 
1.9% (4/203) were anti-HBcoreAb-positive, and 6.5% (30/459) had 
occult hepatitis B infec tion.[20] Another study assessed the efficacy 
of universal vaccination 5 years after the implementation of the 
programme in 598 infants from Limpopo Province aged 8 - 72 months 
(mean 23.3). Of the infants, 86.8% (519/598) were anti-HBsAb-
positive (titre ≥10 mIU/ml), 0% HBsAg-positive and 0% HBV DNA-
positive; however, 0.9% (5/582) of infants aged 8 - 11 months were 
anti-HBcoreAb-positive.[22] Similarly, assessment of the efficacy of 
universal HBV vaccination in 770 healthy 18-month-old babies from 
rural areas of the nine provinces 1 year after vaccination revealed that 
87% were anti-HBsAb-positive (titre ≥10  mIU/ml), 0.4% HBsAg-
positive and 0.5% anti-HBcoreAb-positive, compared with historical 
controls of 10.1% HBsAg seroprevalence in children aged 0 - 6 years.[23]
Influence of HIV
HIV/HBV co-infection increases the risk of perinatal transmission. 
Reduced seroprotection in under-2-year-old HIV-positive v. negative 
children has been demonstrated. Here 78.1% (57/73) v. 85.7% 
(197/230) were anti-HBsAb-positive (titre ≥10 mIU/ml) and 2.7% 
(2/73) v. 0.4% (1/230) HBsAg-positive, with an equivalent anti-
HBcoreAb positivity of 3% and 2.7%, respectively.[24] A 2007 antenatal 
study comparing 1 420 HIV-positive and negative mothers noted 
higher anti-HBcoreAb positivity (39.2% v. 30.1%) in HIV-infected 
women, while 6.2% were HBsAg-positive.[25]
HIV also reduces transfer of maternal anti-HBs. Only 21% of HIV-
exposed v. 54% of unexposed babies had protective levels of anti-HBs, 
suggesting that 79% of babies born to HIV-positive mothers have no 
protective anti-HBs until after the first hepatitis B vaccination at 6 
weeks of age.[3,26] Breakthrough infections can occur, mainly in HIV-
exposed/infected babies.[24]
In 9 355 pregnant women from antenatal clinics in the Western 
Cape Province, no difference was seen between prevalences of 
HBsAg in HIV-positive and negative women (3.4% (53/1 543) 
v. 2.9% (44/1  546)) and HBeAg (18.9% (10/53) v. 17.1% (7/41)). 
However, HBV DNA levels were much higher in HIV-positive 
women, at 9.72 × 107 IU/ml v. 1.19 × 106 IU/ml in HIV-negative 
women, implying that the risk of perinatal transmission would be 
elevated. [27]
Need for a birth-dose vaccine
Although universal infant vaccination in SA has demonstrated 
increased population immunity to hepatitis B, there is still significant 
room for improvement given the absence of screening of pregnant 
women for HBsAg as well as the absence of a catch-up vaccination 
programme such as that implemented in Taiwan. Full coverage with 
three doses needs to be achieved, especially in rural areas where 
HBsAg seroprevalence is highest. To prevent perinatal transmission, 
a birth dose of the vaccine preferably needs to be administered within 
12 hours of delivery, and certainly within 24 hours. The hepatitis B 
monovalent vaccine can be administered together with oral polio 
and BCG. SA must consider a four-dose schedule consisting of a 
monovalent birth dose followed by three doses of monovalent vaccine, 
given together with the routine infant vaccines or as a combination 
vaccine at 6, 10 and 14 weeks. Challenges will be faced in rural areas 
where there is a higher prevalence of hepatitis B, home births occa-
sionally occur and birth BCG coverage is lower (70 - 79%).[3] Studies 
have confirmed the thermostability of HBV vaccines outside the cold 
chain, assisting access to the birth dose in rural areas.[29] A four-dose 
schedule, essentially requiring the addition of a birth dose to the 
existing schedule, is slightly more costly than a three-dose schedule. 
However, it is easier to implement and does not immunologically 
compromise infants who may not access a birth dose. A four-dose 
approach is also recommended for improved immunogenicity if 
penta- or hexavalent vaccines are used in the EPI schedule.
It is unfortunate that recent a request to GAVI, co-signed by 
76 global groups, to fund a birth-dose vaccine in all countries not 
undertaking this routinely, has not been favourably received.
FORUM
612       September 2014, Vol. 104, No. 9
Adolescent booster vaccine
Immunity from vaccination, although good, tends to decline at a 
time when there is increased risk of acquisition of hepatitis B due 
to sexual activity or risky lifestyle behaviour such as injecting drug 
use. A Chinese study assessed the long-term efficacy of postnatal 
active-passive vaccination (HBIG) in 8  733 high-school students. 
Among those who did not receive HBIG, there was a significant 
negative association between hepatitis B vaccination dosage and 
HBsAg positivity. The adjusted odds ratios for those who received 
4, 3 and 1 -  2 doses were 1.00, 1.52 (95% confidence interval (CI) 
0.91 - 2.53) and 2.85 (95% CI 1.39 - 5.81), respectively. Notably, one-
sixth of students who had received four-dose coverage had lost their 
immunological memory against HBsAg by the age of 15 years.[28]
Conclusion
A strong case exists for the implementation of a birth dose of hepatitis 
B vaccine in addition to the current schedule, as recommended by 
the WHO, to decrease the risk of perinatal transmission, prevent 
breakthrough infections, and decrease HBsAg carriage in HIV-
positive babies. An adolescent booster dose, although not routinely 
recommended, merits consideration, as immunological memory 
against HBsAg is lost in a significant number of adolescents by the 
age of 15 years.
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